Dialysis Modalities and HDL Composition and Function

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2015 Mar 7

PMID 25745027

Citations 52

Authors

Michael Holzer

Gernot Schilcher

Sanja Curcic

Markus Trieb

Senka Ljubojevic

Tatjana Stojakovic

Hubert Scharnagl

Chantal M Kopecky

Alexander R Rosenkranz

Akos Heinemann

Gunther Marsche

Affiliations

Soon will be listed here.

Abstract

Lipid abnormalities may have an effect on clinical outcomes of patients on dialysis. Recent studies have indicated that HDL dysfunction is a hallmark of ESRD. In this study, we compared HDL composition and metrics of HDL functionality in patients undergoing hemodialysis (HD) or peritoneal dialysis (PD) with those in healthy controls. We detected a marked suppression of several metrics of HDL functionality in patients on HD or PD. Compositional analysis revealed that HDL from both dialysis groups shifted toward a more proinflammatory phenotype with profound alterations in the lipid moiety and protein composition. With regard to function, cholesterol efflux and anti-inflammatory and antiapoptotic functions seemed to be more severely suppressed in patients on HD, whereas HDL-associated paraoxonase activity was lowest in patients on PD. Quantification of enzyme activities involved in HDL metabolism suggested that HDL particle maturation and remodeling are altered in patients on HD or PD. In summary, our study provides mechanistic insights into the formation of dysfunctional HDL in patients with ESRD who are on HD or PD.

Citing Articles

Association of Small HDL Subclasses with Mortality Risk in Chronic Kidney Disease.

Stadler J, Borenich A, Pammer A, Emrich I, Habisch H, Madl T Antioxidants (Basel). 2025; 13(12.

PMID: 39765838 PMC: 11673888. DOI: 10.3390/antiox13121511.

Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews.

Xu Z, Yang S, Cui L BMC Nephrol. 2024; 25(1):400.

PMID: 39511510 PMC: 11542271. DOI: 10.1186/s12882-024-03808-3.

High-density lipoprotein functionality in cholesterol efflux in early childhood is related to the content ratio of triglyceride to cholesterol.

Futatsugi A, Tozuka M, Horiuchi Y, Ohkawa R, Kosho T Sci Rep. 2024; 14(1):23323.

PMID: 39375444 PMC: 11458590. DOI: 10.1038/s41598-024-74699-5.

Serum HDL-C subfractions as predictors of cardiovascular calcification in hemodialysis patients: novel insights and clinical implications.

Li D, Sun W, Zhou X, Wen Y, Zou Y Front Med (Lausanne). 2024; 11:1391057.

PMID: 39144664 PMC: 11322615. DOI: 10.3389/fmed.2024.1391057.

The importance of paraoxonase 1 activity in chronic kidney disease.

Samouilidou E, Liaouri A, Kostopoulos V, Nikas D, Grapsa E Ren Fail. 2024; 46(2):2376930.

PMID: 38982880 PMC: 11238655. DOI: 10.1080/0886022X.2024.2376930.

References

Burkart J . Metabolic consequences of peritoneal dialysis. Semin Dial. 2005; 17(6):498-504. DOI: 10.1111/j.0894-0959.2004.17610.x. View

Cheung M, Wolfbauer G, Deguchi H, Fernandez J, Griffin J, Albers J . Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology. Biochim Biophys Acta. 2009; 1791(3):206-11. PMC: 2733856. DOI: 10.1016/j.bbalip.2008.12.010. View

Kontush A, Chapman M . Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010; 21(4):312-8. DOI: 10.1097/MOL.0b013e32833bcdc1. View

Marsche G, Saemann M, Heinemann A, Holzer M . Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol Ther. 2012; 137(3):341-51. DOI: 10.1016/j.pharmthera.2012.12.001. View

Zewinger S, Speer T, Kleber M, Scharnagl H, Woitas R, Lepper P . HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol. 2014; 25(5):1073-82. PMC: 4005298. DOI: 10.1681/ASN.2013050482. View

Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C . Uremia alters HDL composition and function. J Am Soc Nephrol. 2011; 22(9):1631-41. PMC: 3171935. DOI: 10.1681/ASN.2010111144. View

Kennedy D, Tang W, Fan Y, Wu Y, Mann S, Pepoy M . Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc. 2013; 2(2):e000104. PMC: 3647254. DOI: 10.1161/JAHA.112.000104. View

Kotani K, Kimura S, Gugliucci A . Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease. J Physiol Biochem. 2011; 67(3):437-41. DOI: 10.1007/s13105-011-0092-4. View

Vaziri N, Navab K, Gollapudi P, Moradi H, Pahl M, Barton C . Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc. 2011; 103(6):524-33. PMC: 3276406. DOI: 10.1016/s0027-9684(15)30368-0. View

10.

Sattler W, Mohr D, Stocker R . Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol. 1994; 233:469-89. DOI: 10.1016/s0076-6879(94)33053-0. View

11.

Garibotto G, Bonanni A, Verzola D . Effect of kidney failure and hemodialysis on protein and amino acid metabolism. Curr Opin Clin Nutr Metab Care. 2011; 15(1):78-84. DOI: 10.1097/MCO.0b013e32834d9df6. View

12.

Pahl M, Ni Z, Sepassi L, Moradi H, Vaziri N . Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). Nephrol Dial Transplant. 2009; 24(8):2541-6. PMC: 2727299. DOI: 10.1093/ndt/gfp120. View

13.

Moradi H, Streja E, Kashyap M, Vaziri N, Fonarow G, Kalantar-Zadeh K . Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant. 2014; 29(8):1554-62. PMC: 4106641. DOI: 10.1093/ndt/gfu022. View

14.

Yamamoto S, Yancey P, Ikizler T, Jerome W, Kaseda R, Cox B . Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 2012; 60(23):2372-9. PMC: 9667707. DOI: 10.1016/j.jacc.2012.09.013. View

15.

Moradi H, Pahl M, Elahimehr R, Vaziri N . Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res. 2009; 153(2):77-85. DOI: 10.1016/j.trsl.2008.11.007. View

16.

Saemann M, Poglitsch M, Kopecky C, Haidinger M, Horl W, Weichhart T . The versatility of HDL: a crucial anti-inflammatory regulator. Eur J Clin Invest. 2010; 40(12):1131-43. DOI: 10.1111/j.1365-2362.2010.02361.x. View

17.

Vaziri N, Navab M, Fogelman A . HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010; 6(5):287-96. DOI: 10.1038/nrneph.2010.36. View

18.

Hu M, Zhang J, Wang W, Wu W, Ma Y, Chen W . The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin. 2011; 32(10):1253-8. PMC: 4010081. DOI: 10.1038/aps.2011.127. View

19.

Norata G, Pirillo A, Ammirati E, Catapano A . Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2011; 220(1):11-21. DOI: 10.1016/j.atherosclerosis.2011.06.045. View

20.

Aviram M, Rosenblat M . Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol. 2008; 477:259-76. DOI: 10.1007/978-1-60327-517-0_20. View